Clinical trials: Somatic Disorders
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Endometriosis
Somatic Stem Cells in Endometriosis
Human endometrium is a very dynamic tissue characterized by cyclical process of proliferation, differentiation and cellular shedding as part of each menstrual cycle. This issue suggests the presence of somatic stem cells.
- Trial name
- NCT01412138
- Testing
- genetic analysis
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Igenomix
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Diabetic Neuropathic Ulcer
Allogeneic ABCB5-positive Stem Cells for Treatment of DFU "Malum Perforans"
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound surface area reduction of Diabetic Foot Ulcers) and safety (by monitoring adverse events) of two doses of the allogeneic investigational…
- Trial name
- NCT03267784
- Testing
- allo-APZ2-DFU
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- RHEACELL GmbH & Co. KG
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
VEXAS Syndrome
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome.
- Trial name
- NCT07748624
- Testing
- Arumakimig, Oral glucocorticoids
- Where
- 4 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
VEXAS, VEXAS Syndrome
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.
- Trial name
- NCT06782373
- Testing
- Pacritinib
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Swedish Orphan Biovitrum
Rabies
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
The aim of the study is to document the safety and immunogenicity of Purified Vero Rabies Vaccine (VRVg) when given in a simulated post-exposure regimen, i.e.
- Trial name
- NCT01877395
- Testing
- Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
- Where
- 5 sites in United States
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis A Vaccine
Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine
This is a Phase Ⅲ, open-label, single arm design combined with randomized, double-blind, active-controlled design trial to assess the immunogenicity and safety of different specifications of Healive® (the 0.5 mL pediatric dosage…
- Trial name
- NCT07793227
- Testing
- Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed)
- Where
- Vietnam
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Peripheral Arterial Occlusive Disease
Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one…
- Trial name
- NCT03339973
- Testing
- allo-APZ2-PAOD
- Where
- 18 sites in Austria, Czechia and 3 more
- Volunteers
- 24 people
- Sponsor
- RHEACELL GmbH & Co. KG
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Myocardial Infarction
Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle
Certain types of cells located in bone marrow may help the body recover after an injury. These cells may be able to help the body repair heart muscle that has been damaged from a heart attack.
- Trial name
- NCT00361855
- Testing
- NX-CP105
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuronyx
Ovarian Cancer
Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer
A phase II, multi-center, open-label, single-arm, non-randomized study to evaluate the efficacy, safety and tolerability of IMP4297 capsules in subjects with germline and/or somatic BRCA1/2 mutated advanced ovarian cancer in china
- Trial name
- SABRINA (NCT04089189)
- Testing
- IMP4297
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Impact Therapeutics, Inc.
Anxiety Disorders, Depression
Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients
To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).
- Trial name
- NCT00546923
- Testing
- Venlafaxine XR
- Volunteers
- 210 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Pain, Chronic Pain (Back / Neck)
Combination of Equisetum Arvense and Palmitoylethanolamide (PEA) for the Management of Patients With Chronic Pain in a Before-after Study
Chronic pain is a type of pain that lasts or recurs for a period of more than three months. Due to the physical, psychological, and socio-relational consequences of chronic pain for the person experiencing it, it has been…
- Conditions
- Chronic Pain, Chronic Pain (Back / Neck), Pain (Visceral, Somatic, or Neuropathic), Pain Management
- Trial name
- Assonal®️PEA (NCT07110480)
- Testing
- Supplement
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- noiVita Srls
Rabies
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
The aim of the study is to document immunogenicity and safety of VRVg in a pre-exposure regimen in healthy children and adolescents aged 2 to 17 years.
- Trial name
- NCT01930357
- Testing
- Purified Vero Rabies Vaccine Serum Free (VRVg), Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
- Where
- 2 sites in Philippines
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation.
- Trial name
- NCT02042378
- Testing
- Rucaparib
- Where
- 8 sites in United States, Israel
- Volunteers
- 19 people
- Sponsor
- pharmaand GmbH
Acromegaly
Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the…
- Trial name
- ACROSCREEN (NCT02020967)
- Testing
- Non-interventional cross-sectional survey
- Where
- 2 sites in Russia
- Volunteers
- 367 people
- Sponsor
- Ipsen